|1.||Hückelhoven, Angela G: 1 article (08/2015)|
|2.||Mueller-Schmucker, Sandra M: 1 article (08/2015)|
|3.||Etschel, Jennifer K: 1 article (08/2015)|
|4.||Harrer, Thomas: 1 article (08/2015)|
|5.||Harrer, Ellen G: 1 article (08/2015)|
|6.||Zitzelsberger, Kathrin: 1 article (08/2015)|
|7.||Bergmann, Silke: 1 article (08/2015)|
|8.||Scadden, David T: 1 article (06/2013)|
|9.||Brander, Christian: 1 article (06/2013)|
|10.||Mothe, Beatriz: 1 article (06/2013)|
06/01/2006 - "The immunodominant HLA-A2-restricted Gag epitope, SLYNTVATL (SL9), is considered to be a poor immunogen because reactivity to it is rare in acute infection despite its paradoxical dominance in patients with chronic infection. "
08/01/2004 - "During the chronic phase of HIV-1 infection, up to 75% of the HIV-infected individuals who express the histocompatibility leukocyte Ag (HLA)-A*0201 recognize the Gag p17 SLYNTVATL (aa residues 77-85) epitope (SL9). "
01/15/2001 - "In chronic infection, the dominant HLA-A*0201-restricted CTL response is directed towards the epitope SLYNTVATL ("SL9") in p17 Gag (residues 77-85). "
|2.||Human Influenza (Influenza)
08/15/2015 - "It has been reported that HIV-1-specific cytotoxic T cells (CTL) recognizing the HLA-A2-restricted p17 epitope SLYNTVATL (SL9) can cross-react with the HLA-A2-restricted influenza matrix epitope GILGFVFTL (GL9). "
06/01/2013 - "Here we studied the possibility of using defined HLA-A*02:01-restricted CTL epitopes from influenza matrix protein (GL9, GILGFVFTL) and HIV Gag p17 (SL9, SLYNTVATL) to elicit a cutaneous delayed-type hypersensitivity (DTH) reaction. "
|1.||influenza matrix peptide (58-66)
|3.||HLA-A Antigens (HLA-A)